MDAIWNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Spectral AI, Inc.

Spectral AI, Inc. is a U.S.-based medical technology company focused on artificial intelligence for wound assessment and burn evaluation. Its core platform, DeepView System, combines imaging hardware with software intended to support clinical decision-making in healthcare and military settings through its operating company and related subsidiaries.

Liikevaihto19,7milj. USD
−33,6 %v/v
Liikevoitto (EBIT)−8,6milj. USD
−30,7 %v/v
EBIT-marginaali−43,8%
−21,5 %-yks.v/v
Nettotulos−7,6milj. USD
+50,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−20−100102030milj. USD2021: EBIT −3,4 milj. USD20212022: 25 milj. USD2022: EBIT −2,6 milj. USD20222023: 18 milj. USD2023: EBIT −13 milj. USD20232024: 30 milj. USD2024: EBIT −6,6 milj. USD20242025: 20 milj. USD2025: EBIT −8,6 milj. USD202520−8,6
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
DeepView System hardware35 %

Proprietary imaging device platform used to capture clinical images for AI analysis.

SaMD / software licensing25 %

Software licensing for DeepView System, including access to algorithm updates and hosting.

Government R&D contracts40 %

Applied research and development work tied to BARDA, MTEC, and DHA programs.

Asiakkaat

Spectral AI sells primarily to government and defense-related research customers today, with BARDA, MTEC, and DHA supporting development of the DeepView System for burn evaluation. Its commercial model is aimed at hospitals, clinics, and site-of-service providers that would use the platform for wound and burn assessment once broadly deployed.

U.S. government research agencies

BARDA, MTEC, and DHA fund DeepView development for burn and battlefield applications.

Military and defense medical users

Military healthcare programs use handheld burn evaluation tools in field and trauma settings.

Hospitals and burn centers

Clinical sites would buy DeepView for wound and burn assessment and treatment support.

Clinics and site-of-service providers

Outpatient and point-of-care settings would use the system for faster triage and workflow support.

Strategia

Spectral AI’s strategy is to convert DeepView from a development-stage platform into a commercial product with both device and recurring software revenue. The company is also building a healthcare-focused AI intellectual property portfolio through Spectral IP, while using government contracts to validate the burn indication and support product development.

Commercialize DeepView SystemKeskipitkä aikaväli

Moves the company from contract-funded development toward product sales and software licensing.

Advance burn indication validationLyhyt aikaväli

Clinical and military validation supports adoption and reimbursement discussions.

Expand healthcare AI IP portfolioKeskipitkä aikaväli

Additional intellectual property can strengthen differentiation and optionality.

Maantiede

The company is headquartered in the United States and its disclosed contract activity is centered on U.S. government programs. Its commercial pricing is intended to be set by country and site of service, indicating a future multi-market rollout rather than a single domestic-only model.

Riskit

The business depends on successful clinical validation, regulatory acceptance, and eventual commercial adoption of a novel AI-enabled medical device platform. It also relies heavily on government-funded development programs, so delays, milestone failures, or changes in public-sector funding can materially affect execution and revenue visibility.

Järjestetty vakavuuden mukaan
Dependence on government contract fundingKorkea

A large share of current activity is tied to BARDA, MTEC, and DHA programs with milestone-based funding.

Kohdistuu: U.S. government research revenue

Clinical validation and adoption riskKorkea

DeepView must prove accuracy and utility before broad hospital and military adoption.

Kohdistuu: Burn and wound assessment market

Early-stage commercialization riskKorkea

The company is still transitioning from development contracts to product revenue.

Kohdistuu: Future device and software sales

Regulatory and reimbursement uncertaintyKeskitaso

Medical software and imaging products may face approval, labeling, and reimbursement hurdles.

Kohdistuu: SaMD commercialization

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition on government contracts

BARDA, MTEC, and DHA work may be recognized over time or by milestone, affecting timing and comparability.

Vaikutus: Research and development revenue

Warrant liabilities

Public and private warrants may be measured at fair value with changes flowing through earnings.

Vaikutus: Other income/expense and net loss

Fair value of debt and stock-based compensation

The company uses estimates for note payable valuation and equity awards, which can move reported expenses.

Vaikutus: Operating and non-operating results

Income tax valuation allowances

As a development-stage company, deferred tax assets may not be fully realizable.

Vaikutus: Tax provision and balance sheet

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Spectral AI, Inc. (MDAIW) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo